Single nucleotide polymorphism in PTEN-Long gene: A risk factor in chronic myeloid leukemia

• Published in: Gene Vol. 694; pp. 71 - 75
• Main Authors: Ferri, C., Weich, N., Gutiérrez, L., De Brasi, C., Bengió, M.R., Zapata, P., Fundia, A., Larripa, I.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 30-04-2019
• Subjects: BCR-ABL1; Chronic myeloid leukemia; Polymorphism; PTEN-Long; CML; OR; TKIs; PTEN; Chronic myeloid leukemia; bp; PTEN-L; qRT; SNP; HWE; BCR-ABL1; PTEN-Long; ARMS-PCR; Polymorphism
• ISSN: 0378-1119; 1879-0038
• DOI: 10.1016/j.gene.2019.01.038

The BCR-ABL1 oncogene is associated with chronic myeloid leukemia (CML) pathogenesis, but the molecular mechanisms that initiate leukemogenesis are still unclear. Cancer pathogenesis has been associated with genetic alterations that may lead to inactivation of tumor suppressor genes. Phosphatase and tensin homolog (PTEN) is frequently deleted or inactivated in various tumors. A recently discovered variant of PTEN, PTEN-Long (PTEN-L), results from an alternative translation initiation site located upstream of the canonic AUG and generates a protein of 576 amino acids instead the expected protein of 403 amino acids. A 16 bp perfect palindromic motif centered on the PTEN-L CUG513 start codon is required for translation initiation. A single nucleotide polymorphism (SNP) of PTEN-L gene rs12573787 is located on the first exon respect to the CUG initiation site. In this case-control study we evaluated the association of genetic variants in PTEN-L with CML risk and therapy response in the Argentine population. The allele A of SNP rs12573787 was found to be associated with CML risk OR (95% CI) 1.71 (1.11–2.63) p = 0.016, which resulted consistent by multivariate analysis adjusted by gender and age. According to previous evidence that CML is more frequent in males, we found that the genetic risk of CML was confined to this gender. Unexpectedly, we also found this association confined to CML patients older than 45 years old. To our knowledge, this is the first time that PTEN-L rs1257378 was studied in CML suggesting that the variant A allele is a risk factor for CML development but, no association with the failure to TKIs treatment was found.
•This is the first report that assesses the PTEN-long SNP rs12573787 in CML risk and outcome.•Variant A allele and genotypes (G/A + A/A) were associated with CML risk.•Males and older patients with variant genotypes exhibited an increased CML risk.•No association with the response to TKIs treatment was found.•Argentine alleles frequencies fit with those reported worldwide, but differ from East Asians.